Literature DB >> 22532521

Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.

Pratap Neelakantan1, David Marin, Mike Laffan, John Goldman, Jane Apperley, Dragana Milojkovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22532521      PMCID： PMC3436248          DOI： 10.3324/haematol.2012.064618

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway.

Authors:  L S Quek; J M Pasquet; I Hers; R Cornall; G Knight; M Barnes; M L Hibbs; A R Dunn; C A Lowell; S P Watson
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

Review 2.  Clinical utility of the PFA-100.

Authors:  Emmanuel J Favaloro
Journal:  Semin Thromb Hemost       Date:  2009-02-12       Impact factor: 4.180

3.  Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Xin Han; Hagop Kantarjian; Jorge Cortes
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

4.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

Authors:  Thomas O'Hare; William C Shakespeare; Xiaotian Zhu; Christopher A Eide; Victor M Rivera; Frank Wang; Lauren T Adrian; Tianjun Zhou; Wei-Sheng Huang; Qihong Xu; Chester A Metcalf; Jeffrey W Tyner; Marc M Loriaux; Amie S Corbin; Scott Wardwell; Yaoyu Ning; Jeffrey A Keats; Yihan Wang; Raji Sundaramoorthi; Mathew Thomas; Dong Zhou; Joseph Snodgrass; Lois Commodore; Tomi K Sawyer; David C Dalgarno; Michael W N Deininger; Brian J Druker; Tim Clackson
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

5.  Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets.

Authors:  Y Ezumi; K Shindoh; M Tsuji; H Takayama
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307
  5 in total
  14 in total

1.  The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.

Authors:  Aziz Nazha; Carlos G Romo; Hagop Kantarjian; Jorge Cortes
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

Review 2.  The argument for using imatinib in CML.

Authors:  Simone Claudiani; Jane F Apperley
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.

Authors:  Cassandra P Loren; Joseph E Aslan; Rachel A Rigg; Marie S Nowak; Laura D Healy; András Gruber; Brian J Druker; Owen J T McCarty
Journal:  Thromb Res       Date:  2014-11-18       Impact factor: 3.944

Review 4.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

5.  Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.

Authors:  Geoffrey D Miller; David W Woessner; Monika J Sirch; Carol S Lim
Journal:  Mol Pharm       Date:  2013-08-20       Impact factor: 4.939

6.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

7.  Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.

Authors:  Yllka Latifi; Federico Moccetti; Melinda Wu; Aris Xie; William Packwood; Yue Qi; Koya Ozawa; Weihui Shentu; Eran Brown; Toshiaki Shirai; Owen J McCarty; Zaverio Ruggeri; Javid Moslehi; Junmei Chen; Brian J Druker; Jose A López; Jonathan R Lindner
Journal:  Blood       Date:  2019-01-28       Impact factor: 25.476

Review 8.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

9.  Computational Drug Target Screening through Protein Interaction Profiles.

Authors:  Santiago Vilar; Elías Quezada; Eugenio Uriarte; Stefano Costanzi; Fernanda Borges; Dolores Viña; George Hripcsak
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

Review 10.  Vascular toxic effects of cancer therapies.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-26       Impact factor: 32.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.